BLU Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2023 @ 15:59):

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications...

Stats
Today's Volume	2.84M
Average Volume	5.38M
Market Cap	1.87B
EPS	$0 ( 2024-03-19 )
Next earnings date	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.20
ATR14	$0.119 (0.81%)

Volume Correlation

Long: 0.19 (neutral)

Short: 0.64 (weak)

Signal:(78.88) Neutral

BELLUS Health Inc Correlation

10 Most Positive Correlations
SRRA	0.976
CYCN	0.966
NISN	0.961
TESS	0.955
MNTV	0.954
SCR	0.952
CSII	0.948
KIN	0.943
ALZN	0.942
LEGN	0.938

10 Most Negative Correlations
JCTCF	-0.943
CRUS	-0.942
MTEX	-0.939
CRTD	-0.936
VRAY	-0.935
CFBK	-0.934
CHDN	-0.929
PEAR	-0.925
PTE	-0.924
EVER	-0.922

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BELLUS Health Inc Correlation - Currency/Commodity

0.91
( very strong )

0.89
( strong )

-0.75
( moderate negative )

0.81
( strong )

-0.18
( neutral )

-0.62
( weak negative )

BELLUS Health Inc Financials

Annual	2022
Revenue:	$16 000.00
Gross Profit:	$-3.51B (-21 967 104.08 %)
EPS:	$-0.660

FY	2022
Revenue:	$16 000.00
Gross Profit:	$-3.51B (-21 967 104.08 %)
EPS:	$-0.660

FY	2021
Revenue:	$16 000.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.207

FY	2020
Revenue:	$15 000.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.540

Financial Reports:

No articles found.

BELLUS Health Inc

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.